Creation of STALLERGENES by the Institut Mérieux, a world leader in vaccines

STALLERGENES enters the Benelux and North African markets.

STALLERGENES markets products in Germany

STALLERGENES develops and supplies one of the first anti-allergies vaccines to be administered orally.

First NPP* automated production chain implemented by STALLERGENES

Merger of STALLERGENES with the Allergen Division - Institut Pasteur

Expansion of STALLERGENES in Greece, Spain, Portugal and Turkey

Acquisition of STALLERGENES by Wendel Investissement

Launch of Staloral^® (allergen immunotherapy by sublingual delivery)

Creation of a subsidiary in Germany and purchase of a laboratory in Belgium

- Creation of a subsidiary in Italy and in Central Europe (Czech Republic and Slovakia)

- Establishment in Antony (Paris area)

Introduction of STALLERGENES to the Second Market of the Paris Stock Exchange

- With the purchase of DHS, the allergy division of Bayer Pharma, the STALLERGENES-DHS Group becomes the world's number 2 company in its sector

- Opening of a subsidiary in Spain

- Awarded international ISO 9001 certification

Pursuit of international development in South Africa, Australia, New Zealand and Poland.

STALLERGENES enters the Middle East markets

Launch of Staloral 300^® (desensitisation therapy via sublingual drops) in Europe

Initiation of the first clinical study comparing the efficacy of a recombinant allergen tablet to a current product (Alustal^®)

Launch of a clinical study on the Grasses sublingual tablet, which represents a new therapeutic class and a significant advance for patients

Acquisition of IPI's desensitization activity in Spain and Portugal
Success of the clinical study on the Grasses tablet

- Subsidiary formation for promotional activity in the Czech Republic and in Slovakia

- Submission of the registration dossier for the Grasses desensitisation tablet in Germany, serving as the reference country as part of the European mutual recognition procedure.

- Positive results from the first Proof of concept clinical study comparing the efficacy of a recombinant allergen (Bet v 1) with the current product based on a natural birch pollen extract.

- Initiation of the construction of a new industrial unit at the Antony site.

- Results of the Phase I safety study of the Mites desensitisation tablet.

Signature of an agreement for development and distribution of the desensitisation tablet with the Canadian company, Paladin Labs >>See the press release

Development of a first product candidate as part of the Enhanced Allergens program with a view to pharmaceutical and preclinical development.

Creation of a subsidiary in the Netherlands in partnership with the Dutch company SANMED B.V >> See the press release